HIV-associated lipodystrophy

HIV Medicine

Volumn 2, Issue 3, 2001, Pages 166-173

  Mallon, P W G ^a,b   Cooper, D A ^a,b   Carr, A ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

HIV; Lipoatrophy; Lipodystrophy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; AMPRENAVIR; GEMFIBROZIL; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LOPINAVIR; METFORMIN; NELFINAVIR; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMEN; ADIPOSE TISSUE; ARTICLE; ATHEROSCLEROSIS; BREAST; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LACTIC ACIDEMIA; LIPID STORAGE; LIPODYSTROPHY; NECK; PLASTIC SURGERY; PRIORITY JOURNAL; SYNDROME; TISSUE TRANSPLANTATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARTERIOSCLEROSIS; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIPODYSTROPHY;

EID: 0035194752     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2001.00071.x     Document Type: Article

References (52)

1. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
2. Visceral abdominal-fat accumulation associated with the use of indinavir
3. Description of lipodystrophy in HIV Outpatients Study (HOPS)
4. The Australian prevalence survey of lipodystrophy syndrome
5. Hyperlactatemia and antiretroviral therapy in the Swiss HIV Cohort Study
6. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study
7. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
8. Metabolic effects of indinavir in healthy HIV-seronegative subjects
9. Effects of protease inhibitors on hyperglycaemia, hyperlipidaemia and lipodystrophy: A 5-year cohort study
10. Pathogenesis of HIV protease inhibitor-associated syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance
11. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy
12. Singular case of absence of adipose matter in the upper half of the body
13. Discovery of a lipodystrophy gene: One answer, one hundred questions
14. Lipodystrophies
15. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-related lipodystrophy
16. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPAR/RXR heterodimer
17. Effects of nucleoside reverse transcriptase inhibitors and HIV protease inhibitors on adipogenesis and adipocyte metabolism
18. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
19. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
20. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV infected individuals with peripheral lipoatrophy
21. Lamins in disease: Why do ubiquitously expressed nuclear envelope proteins give rise to tissue-specific disease phenotypes?
22. Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy
23. Lessons from lipodystrophy: LMNA, encoding lamin A/C, in HIV therapy-associated lipodystrophy
24. Obesity, body fat distribution, insulin sensitivity and islet-cell function as explanations for metabolic diversity
25. HIV protease inhibitor-related lipodystrophy syndrome
26. Leptin is a potent anti-diabetic in mice with lipodystrophy and insulin resistance
27. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro
28. HIV protease inhibitors stimulate hepatic triglyceride synthesis
29. Metabolic complications of HAART need for perspective
30. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy
31. Protease inhibitors up-regulate SR-BI and HDL-dependent cholesterol uptake in human macrophages: A mechanism that may enhance foam cell formation
32. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men
33. Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients? Follow-up through June
34. Carotid artery intima-media thickness measured by ultrasonography in normal clinical practice correlates well with atherosclerosis risk factors
35. Endothelial dysfunction is associated with the use of human immunodeficiency virus type 1 protease inhibitors
36. Diagnosis and determinants of subclinical arterial disease in HIV1-infected patients on HAART
37. Premature atherosclerosis in HIV-infected individuals - Focus on protease inhibitor therapy
38. Atherogen lipid profile in HIV-infected patients with lipodystrophy syndrome
39. Metformin in the treatment of HIV lipodystrophy syndrome. A randomised controlled trial
40. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy
41. A randomised, double-blind study of gemfibrozil (GF) for the treatment of protease inhibitor-associated hypertriglyceridaemia
42. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes
43. Effects of the PPAR-activator troglitazone on protease inhibitor associated peripheral insulin resistance
44. HIV protease inhibitor substitution in patients with lipodystrophy: A randomised controlled, open-label, multicentre study
45. A prospective open-label trial of a maintenance nevirapine (NVP)-containing regimen in patients with undetectable viral loads (VL) on protease inhibitor (PI) regimens for at least 6 months
46. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999
47. An open randomised study on the replacement of HIV-1 protease inhibitors by efavirenz in chronically suppressed HIV-1-infected patients with lipodystrophy
48. Switching from PI to ABC improves insulin sensitivity and fasting lipids - 12 month follow-up
49. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice
50. Metabolic and morphological alterations under antiretroviral therapy: Preliminary results of lipodystrophy Italian Multicentre Study (LIMS)
51. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV
52. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: A pilot study